Genexine’s DNA Vaccine Shows Promise As Combo Therapy In Cervical Cancer
Executive Summary
Genexine is poised to continue to focus on developing therapeutic DNA vaccine GX-188E as combination therapy, following Phase II interim results in advanced cervical cancer that show impressive clinical benefit over pembrolizumab monotherapy.